Psychosocial Support for Nitrous Oxide Misuse
Development and Evaluation of a Psychosocial Intervention for Nitrous Oxide Misuse in East London
2 other identifiers
interventional
10
1 country
1
Brief Summary
Nitrous oxide (laughing gas, N₂O) is the third most commonly used recreational drug among young people in the UK. Although it may seem harmless, frequent use can damage the nerves and spinal cord. Vitamin B12 injections can help treat these neurological complications, but continued N₂O use can reduce how effective this treatment is. Some people use N₂O to cope with stress or emotional difficulties, while others may find it hard to stop because of cravings or habits. These emotional and social difficulties can negatively affect recovery, wellbeing, and quality of life. Our team has developed a new brief support programme for people experiencing mild to moderate emotional and social difficulties related to N₂O use. The programme provides information and practical strategies to help people cope, manage emotions, and prevent problems from worsening. It is delivered by a trained facilitator over up to four weekly sessions, either in-person or remotely. In this study, the support programme will be introduced to patients attending the Royal London Hospital clinic for N₂O related neurological harms. Ten participants will receive the programme alongside their usual care. Participants will complete questionnaires before and after the programme to monitor mental health, quality of life, and dependence on N₂O. The research team will evaluate whether the programme was delivered as intended and whether participants remained engaged. Participants will be invited to take part in an interview to feedback on their experiences and suggest improvements before the programme is tested in a larger study. Participation will last up to 8 hours in total over approximately 9 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 1, 2026
CompletedFirst Posted
Study publicly available on registry
July 21, 2026
CompletedStudy Start
First participant enrolled
September 14, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
August 13, 2027
Study Completion
Last participant's last visit for all outcomes
September 13, 2027
July 21, 2026
July 1, 2026
11 months
July 1, 2026
July 16, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Feasibility response rate
Response rates
12 months
Feasibility uptake
Study uptake
12 months
Feasibility drop out
Drop outs and completion
12 months
Secondary Outcomes (3)
Fidelity accuracy
12 months
Fidelity quality
12 months
Acceptability
12 months
Study Arms (1)
Psychosocial intervention
EXPERIMENTALA brief manualised psychosocial intervention comprising information provision, psychoeducation, goal setting, coping strategies, self-management strategies, and Cognitive Behavioural Therapy techniques (Inc. Mindfulness, cognitive reframing). The intervention will be tailored to individual needs, informed by questionnaire results, goal setting, homework activities, and open discussion.
Interventions
A brief manualised psychosocial intervention comprising information provision, psychoeducation, goal setting, coping strategies, self-management strategies, and Cognitive Behavioural Therapy techniques (Inc. Mindfulness, cognitive reframing). The intervention will be tailored to individual needs, informed by questionnaire results, goal setting, homework activities, and open discussion.
Eligibility Criteria
You may qualify if:
- Confirmed clinical neurological diagnosis related to N₂O use.
- Experiencing mild to moderate psychological distress.
- Aged 16-65 years.
- Able to communicate in English.
- Able and willing to give informed consent.
You may not qualify if:
- Other causes of neurological symptoms.
- Currently receiving another structured psychosocial intervention.
- Severe psychiatric distress.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Queen Mary University of London
London, E1 4NS, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 1, 2026
First Posted
July 21, 2026
Study Start (Estimated)
September 14, 2026
Primary Completion (Estimated)
August 13, 2027
Study Completion (Estimated)
September 13, 2027
Last Updated
July 21, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share
Patient data only collected for the purpose of this study.